Academic Training in Hematology

描述（由申请人提供）：这是加州大学洛杉矶分校David Geffen医学院PHS机构国家服务奖（T32 HL66992）的竞争性更新申请的重新提交，旨在为血液学学术生涯准备博士后研究员。该奖项于2002年7月启动，在血液学/肿瘤医学培训的第2年和第3年提供4个奖学金名额。项目主管是Victor Marder，医学博士，副项目主管是Donald Kohn，医学博士。为了与NHLBI培训非恶性血液学研究员的使命保持一致，我们对我们的项目在领导、研究重点、研究人员的选择和资助方面做出了重大改变。值得注意的是：1)任命了一名儿科血液学研究员，他将研究镰状细胞病的基因移植；2)取消了白血病的现有研究重点；3)重组了培训基金的领导机构，以反映我们对非恶性血液学的关注。自2002年以来，已有22名研究员在加州大学洛杉矶分校完成了他们的奖学金，其中15人（68%）积极参与研究，12人（55%）在大学或医学中心担任全职教师或在行业中担任全职研究职位，3人积极从事临床研究

DESCRIPTION (provided by applicant): This is a resubmission of a competitive renewal application for a PHS Institutional National Service Award (T32 HL66992) at the David Geffen School of Medicine at UCLA to prepare post-doctoral fellows for an academic career in Hematology. This award was initiated in July, 2002, and supports 4 fellowship slots in years 2 and 3 of Hematology/Medical Oncology training. The Program Director is Victor Marder, MD, and the Associate Program Director is Donald Kohn, MD. In keeping with the NHLBI mission for training fellows in non-malignant hematology, we have made significant changes in our program regarding leadership, research foci, and selection of and funding of fellows for their research years of training. Of note are 1) the appointment of a pediatric hematology fellow who will study gene transplantation in sickle cell disease, 2) the elimination of an existing research focus in Leukemia, and 3) re-organization of Training Grant leadership to reflect our focus on non-malignant hematology. Since 2002, 22 fellows have completed their fellowship at UCLA, 15 of which (68%) are actively involved in research, 12 (55%) as full-time faculty at a University or Medical Center or in a full-time research position in industry, and 3 with active clinical research programs as part of their practice, including 2 who have voluntary university appointments. In the last 3 years (2010-2012), 7 of 8 graduates (87.5%) entered full- or part-time university or industry positions of research. All fellows entering the program are Training Grant Eligible (TGE). The faculty consists of 31 academic scientists and physicians, 89% of whom have NIH grant funding, grouped into 3 research foci, Hematopoiesis and Stem Cell Biology (Don Kohn, MD, Director), Lymphocyte Biology (John Timmerman, MD, Director) and Coagulation and Vascular Biology (Victor Marder, MD, Director). Interaction with other training programs in complementary disciplines, notably those in the Broad Stem Cell Research Center, the T32 Training Grant in Developmental Hematology, and the NCI T32 Training Grant in Medical Oncology, emphasizes the resources available to meet our mission of basic and translational research careers. A core curriculum is offered to all fellows, including a "Clinical Research Course", which covers subjects on research design and analysis, ethics, regulatory issues, grant preparation and responsible conduct of research. Fellows are encouraged to obtain an advanced degree as part of the STAR program, and 2 have obtained the Master's degree and 2 a PhD degree. Formal review of the mentor's effectiveness and the fellow's achievements are prepared by the Steering Committee, made up of the 3 Focus Directors, the PI of the Division Oncology Training Grant (Antoni Ribas, MD, PhD), and the Director of the Division Fellowship Training Program (Arash Naeim, MD, PhD). Three research retreats are held each year, fall retreats at which first year research proposals are proposed and second year progress reports are reviewed, and a spring retreat for final reports of graduating fellows. We are proud of our success in training underrepresented Minority candidates, 3 of 13 (23%) since 2007 being Hispanic or African-American.